Abstract
A laboratory evaluation of three slow-release formulations (SRFs) of spinosad tablets, sumilarv granules and du-dim tablets was carried out in 20 liters plastic containers. The tested formulations were applied according to recommended doses to evaluate their efficacy and longevity against Ae. aegypti. The results revealed that the tested SRFs achieved complete inhibition of adult stages emergence of Ae. aegypti in the first four weeks and gave continuous effective with 50-100% for 98, 86 and 78 days post -treatment by using spinosad tablets, sumilarv granules and du-dim tablets respectively. The highest larval mortality was observed for spinosad followed by sumilarv and du-dim, it gave 1.3 folds than sumilarv and 1.1 folds with du-dium, whereas sumilarv and du-dium were more effective on pupal mortality than spinosad. On the other hand, morphological abnormalities were observed in larval and pupal stages of Ae. aegypti as delayed effects by tested formulations. This study highlighted that these SRFs could be used as potential larvicidal compounds in mosquito control programs as a single treatment and provide satisfactory results and continuous control against the dengue vector Ae. aegypti for several weeks.
Highlights
Background document for preparation of WHOAssoc . 2004; 20(2): 176-82.Guidelines for drinking-water quality
Larval stages of Ae. aegypti were collected from breeding habitats in Al-BaladJeddah city and had maintained in the laboratory under controlled conditions of 27±1°C and 70±5% R.H., with 14:10 (L:D) photoperiod
The slow-release formulations used in this study, could naturally derived insecticide spinosad is highly be used as a suitable bioinsecticides alternative for toxic to Aedes and Anopheles mosquito larvae
Summary
Mosquito strain This investigation involved evaluation and determining the efficacy and longevity of three selected slow release formulations under laboratory conditions. Three slow release formulations (SRFs) were used: Spinosad (7.4% tablet) and Du-Dim (diflubenzuron 2 % tablet). They were supplied by Mosquito Research laboratory of the Municipality of Jeddah and Sumilarv (pyriproxyfen 0.5 % WDG) manufactured by Summit Chemical Company Japan, was obtained from Agricultural officeJeddah, Saudi Arabia. The amount of each formulation (0.14gm Spinosad; 1 gm Du-dim tablet; and 0.2gm Sumilarv) required for treating mosquito larvae was determined according to the recommended dosages for field trials as well as by calculating the total volume of water in the container. The plastic containers were inspected daily and larval mortalities were recorded until all larvae either pupated or died. New sets of alive larvae were added to the test containers when complete larval mortality occurred. The data were statistically analyzed to obtain ANOVA and least significant different using SAS (V 9.0)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
